Evidence map›Paper›PMID 38289290›Full record

ReviewEndocrine-related cancer2024

Bioengineered in vitro three-dimensional tumor models in endocrine cancers.

Aleksander Skardal, Hemamylammal Sivakumar, Marco A Rodriguez, Liudmila V Popova, Priya H Dedhia

Open access · greenAbstract readReview
In one paragraph

Review in Endocrine-related cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Aleksander SkardalDepartment of Biomedical Engineering, The Ohio State University, Columbus, Ohio, USA.ORCID 0000-0002-2138-2453
Hemamylammal SivakumarDepartment of Biomedical Engineering, The Ohio State University, Columbus, Ohio, USA.
Marco A RodriguezDepartment of Biomedical Engineering, The Ohio State University, Columbus, Ohio, USA.
Liudmila V PopovaDivision of Surgical Oncology, The Ohio State University and Arthur G. James Comprehensive Cancer Center, Columbus, Ohio, USA.
Priya H DedhiaThe Ohio State University and Arthur G. James Comprehensive Cancer Center, Columbus, Ohio, USA.
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute · USThe Ohio State University · US

Funding

A matrix metalloproteinase biosensor-functionalized metastasis-on-a-chip platform for evaluating adrenocortical carcinoma progressionR21CA277083 · NCI · OHIO STATE UNIVERSITY · PI DEDHIA, PRIYA HARAKH, LEIGHT, JENNIFER · 2023 to 2024
$388k
NCI NIH HHS R21 CA277083
6 · The paper itself

Abstract

Abstract: Endocrine tumors are a heterogeneous cluster of malignancies that originate from cells that can secrete hormones. Examples include, but are not limited to, thyroid cancer, adrenocortical carcinoma, and neuroendocrine tumors. Many endocrine tumors are relatively slow to proliferate, and as such, they often do not respond well to common antiproliferative chemotherapies. Therefore, increasing attention has been given to targeted therapies and immunotherapies in these diseases. However, in contrast to other cancers, many endocrine tumors are relatively rare, and as a result, less is understood about their biology, including specific targets for intervention. Our limited understanding of such tumors is in part due to a limitation in model systems that accurately recapitulate and enable mechanistic exploration of these tumors. While mouse models and 2D cell cultures exist for some endocrine tumors, these models often may not accurately model nuances of human endocrine tumors. Mice differ from human endocrine physiology and 2D cell cultures fail to recapitulate the heterogeneity and 3D architectures of in vivo tumors. To complement these traditional cancer models, bioengineered 3D tumor models, such as organoids and tumor-on-a-chip systems, have advanced rapidly in the past decade. However, these technologies have only recently been applied to most endocrine tumors. In this review we provide descriptions of these platforms, focusing on thyroid, adrenal, and neuroendocrine tumors and how they have been and are being applied in the context of endocrine tumors.

Indexed as

Adrenal Cortex NeoplasmsEndocrine Gland NeoplasmsNeuroendocrine TumorsThyroid NeoplasmsAnimalsHumansMiceOrganoidsbioengineeredin vitromodelsorganoidsthree-dimensional

Identifiers

PMID38289290
PMCPMC11800312
OpenAlexW4391347323

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.